Pacific Biosciences of California, Inc.

Pacific Biosciences of California, Inc.

PACB
Pacific Biosciences of California, Inc.US flagNASDAQ Global Select
1.38
USD
-0.02
- -
428.63MMarket Cap

Total Valuation

Pacific Biosciences of California, Inc. carries a market capitalization of 428.63M, placing it among publicly traded companies globally. Its enterprise value stands at 826.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap428.63M
Enterprise Value826.31M

Share Statistics

Pacific Biosciences of California, Inc. currently has 310.49M shares outstanding.

Shares Outstanding310.49M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 2.49, and the price-to-book ratio stands at -0.15.

PE RatioN/A
PS Ratio2.49
PB Ratio-0.15
P/TBV Ratio-1.21
P/FCF Ratio-3.89
P/OCF Ratio-3.57

Enterprise Valuation

EV / Sales5.16
EV / EBITDAN/A
EV / EBITN/A
EV / FCFN/A

Financial Position

Pacific Biosciences of California, Inc. maintains a current ratio of 5.65, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 29,728.99, indicating elevated leverage, while an interest coverage ratio of -23.20 demonstrates limited ability to service its debt obligations.

Current Ratio5.65
Quick Ratio4.67
Debt / Equity29,728.99
Debt / EBITDA-4.36
Interest Coverage-23.20

Financial Efficiency

Return on Equity (ROE)N/A
Return on Assets (ROA)-15.65
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover1.90

Taxes

Income Tax804,000.00
Effective Tax RateN/A

Stock Price Statistics

Pacific Biosciences of California, Inc.'s stock has declined approximately -18.3432% over the past 52 weeks. The 50-day moving average sits at 1.43, while the 200-day moving average is 1.71.

Beta (5Y)N/A
52-Week Price Change-18.3432%
50-Day Moving Average1.43
200-Day Moving Average1.71
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, Pacific Biosciences of California, Inc. generated 160.03M in revenue and converted that into -128.58M in net income, yielding earnings per share of -0.43. EBITDA reached -161.38M, while operating income came in at -179.08M.

Revenue160.03M
Gross Profit59.99M
Operating Income-179.08M
Pretax Income-127.77M
Net Income-128.58M
EBITDA-161.38M
EBIT-179.08M
Earnings Per Share (EPS)-0.43

Balance Sheet

Pacific Biosciences of California, Inc. holds 275.96M in cash and equivalents against 703.39M in total debt, resulting in a net debt position of 587.83M. Total book value stands at -2.70B, with working capital of 304.16M providing operational flexibility.

Cash & Cash Equivalents275.96M
Total Debt703.39M
Net Debt587.83M
Equity (Book Value)-2.70B
Book Value Per Share-8.95
Working Capital304.16M

Cash Flow

Pacific Biosciences of California, Inc. produced -111.84M in operating cash flow over the past twelve months. After subtracting -9.37M in capital expenditures, free cash flow totaled -121.21M - equivalent to -0.40 per share.

Operating Cash Flow-111.84M
Capital Expenditures-9.37M
Free Cash Flow-121.21M
FCF Per Share-0.40

Margins

Pacific Biosciences of California, Inc. operates with a gross margin of 37.49, reflecting its pricing power and cost economics. The operating margin of -111.90 and net profit margin of -80.34 provide insight into operational efficiency.

Gross Margin37.49
Operating Margin-111.90
Pretax Margin-79.84
Profit Margin-80.34
EBITDA Margin-100.84

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield-0.73
FCF Yield-25.69

Scores

Pacific Biosciences of California, Inc. posts an Altman Z-Score of -8.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-8.24